Stock Performance and Market Context
The stock has been on a downward trajectory for the past two trading sessions, registering a cumulative loss of 3.13%. Today’s closing price of Rs.73 represents the lowest level in the past year, well below its 52-week high of Rs.115. This decline comes despite the stock’s performance today being broadly in line with its sector peers within Pharmaceuticals & Biotechnology.
Technical indicators show Anuh Pharma trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained bearish momentum. This contrasts with the broader market benchmark, the Sensex, which, despite a negative close at 83,049.63 (down 0.62%), remains only 3.74% below its own 52-week high of 86,159.02.
However, the Sensex itself has been under pressure, experiencing a three-week consecutive decline with a cumulative loss of 3.16%. The index’s 50-day moving average remains above its 200-day moving average, indicating a longer-term positive trend despite recent volatility.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Performance and Valuation Metrics
Anuh Pharma’s financial results have reflected subdued growth over recent years. Net sales have expanded at a compound annual growth rate of 13.69% over the last five years, while operating profit growth has been more modest at 7.18% annually. These figures indicate a slower pace of expansion relative to some industry peers.
The company reported a Profit Before Tax (PBT) excluding other income of Rs.8.94 crores in the latest quarter, representing a decline of 29.3% compared to the average of the previous four quarters. Similarly, the Profit After Tax (PAT) for the last six months stood at Rs.15.91 crores, down by 35.19% year-on-year. Return on Capital Employed (ROCE) for the half-year period was recorded at 15.90%, the lowest level observed in recent reporting periods.
Despite these challenges, Anuh Pharma maintains a low average debt-to-equity ratio of zero, reflecting a debt-free capital structure. The company’s Return on Equity (ROE) stands at 11.8%, and it trades at a Price to Book Value ratio of 2.2, suggesting an attractive valuation relative to its historical averages and peer group.
Over the past year, the stock has underperformed significantly, delivering a negative return of 28.37%, while the broader BSE500 index has generated a positive return of 7.49%. Profitability has also contracted, with reported profits falling by 34.4% during the same period.
Shareholding and Promoter Activity
In a notable development, promoters have increased their stake in Anuh Pharma by 1.9% over the previous quarter, now holding 71.82% of the company’s equity. This rise in promoter shareholding may be interpreted as a sign of confidence in the company’s prospects despite recent price declines.
Holding Anuh Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
Mojo Score for Anuh Pharma currently stands at 28.0, with a Mojo Grade of Strong Sell, upgraded from a previous Sell rating on 8 January 2026. The company’s market capitalisation grade is rated 4, reflecting its mid-tier market cap status within the Pharmaceuticals & Biotechnology sector.
Day-to-day price movement today showed a decline of 0.46%, consistent with the sector’s overall performance. The stock’s sustained trading below all major moving averages highlights ongoing downward pressure.
While the Sensex and broader market indices have experienced some volatility, Anuh Pharma’s share price decline to Rs.73 marks a distinct low point for the company over the past year, underscoring the challenges faced in maintaining growth and profitability.
Conclusion
The fall of Anuh Pharma Ltd’s stock to its 52-week low of Rs.73 reflects a combination of subdued financial results, underperformance relative to market benchmarks, and technical weakness in price trends. Despite a solid balance sheet with no debt and an attractive valuation on certain metrics, the company’s recent earnings contraction and slower growth rates have weighed on investor sentiment. Promoter stake increases provide a counterpoint to the price decline, signalling internal confidence amid a challenging market environment.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
